Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral azacitidine maintenance after allogeneic stem cell transplantation in AML or high-risk MDS
2018-001012-30Phase 3Unknown
- Sponsor
- University of Birmingham
- Start
- Nov 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) comparing Oral azacitidine maintenance with Placebo maintenance (2 arms). Primary endpoint: Relapse-free survival. Status: unknown.
02
Drugs
azacitidine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2018-001012-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001012-30.